Arcutis Biotherapeutics Inc (ARQT) News

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Arcutis Announces Promotions on Executive Management Team

Strategic appointments support further growth and position Company for future success WESTLAKE VILLAGE...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities